-
Groundbreaking US astronaut Christina Koch wins top Spanish award
-
BBC eyes compulsory redundancies in cost-cutting drive
-
Trump threatens 'dropping bombs' if Iran doesn't 'behave'
-
EU lawmakers approve 'return hubs' migration reform
-
Oil steadies, stocks rise as US-Iran peace talks approach
-
Global data declaration targets illegal fishing
-
US not 'pulling away' from allies by cutting NATO commitments: Rutte
-
'I'm the boss', Trump tells G7 counterparts
-
Adidas runs out of letter 'V' as German fans snap up World Cup shirts
-
Van Aert out of Tour de France with elbow injury
-
Bernardo Silva signs two-year deal with Real Madrid
-
Louvre museum 'running out of steam', says new director
-
German grid connection deal to boost North Sea wind power
-
G7 leaders applaud Iran, Ukraine progress ahead of tackling AI
-
Sovereignty fears dog AI enthusiasm at France's Vivatech
-
England enter World Cup fray as Ronaldo makes history
-
US military footprint growing in Australia: defence minister
-
France braces for heatwave with canal swimming allowed in Paris
-
Japan puts the heat on suspected ice cream cartel
-
Sovereignty fears to dog AI enthusiasm at France's Vivatech
-
MEXC May Report: SPACEX Launchpad Oversubscribed 15.5x, US Equity Futures Volume Jumps 85%
-
MEXC Prediction Markets Launches Combo to Enable Multi-Event Combination Trading
-
'We have always won': Ebola pioneer still on front line at 84
-
World Cup goals record 'just a number', says Messi
-
Australian far-right leader slams media, 'radical Islam' in testy press briefing
-
Stuffed toys and surfboards: Japan used goods market booms overseas
-
Messi salutes 'beautiful moment' after tying World Cup goals record
-
Putin hosts ASEAN leaders amid G7 pressure on Ukraine war
-
Iranian tankers exit US blockade zone ahead of peace talks
-
'Unstable' Tasmanian devil found after 15 days on the run
-
Magical Messi equals World Cup goals record as Argentina win
-
Messi equals World Cup goalscoring record in Argentina romp
-
Restore Britain, the hard-right party troubling Nigel Farage
-
Trap, neuter, release: Jakarta battles cat-astrophic stray numbers
-
Cuba's historic homes teeter on brink as economy collapses
-
EU lawmakers to approve migrant detention and deportation boost
-
Ronaldo as excited for sixth World Cup as his first, says Martinez
-
Macron winds up G7 with AI, Trump dinner
-
Norway coach hails Haaland after World Cup double
-
US Fed set to hold rates steady at Warsh's first meeting in charge
-
Argentina's Messi plays in record sixth World Cup
-
Kane tells England 'be free in the mind' for World Cup title bid
-
France and two-goal Mbappe roar into World Cup as Messi prepares
-
Trump ballroom cost soars to $600 mn, half from taxpayers: report
-
Swamp Thing: Algae mess with Trump's pool project
-
Haaland double powers Norway to World Cup win over Iraq
-
Sean Penn to direct film on January 6 Capitol assault: US media
-
Arcus Development and Core Silver Provide Update on Proposed Business Combination to Create Tintina Belt Exploration Company Anchored by the Touleary VMS Discovery
-
Global Stem Cells Group (OTC:RMTG) Launches ISSCA Mobile App, Advancing Its Buildout of a Global Digital Ecosystem for Regenerative Medicine
-
Ur-Energy Celebrates 100th Shipment of Yellowcake from Lost Creek ISR Uranium Mine, Wyoming
CTT Pharma Signs LOI with European Company
TAMPA, FL / ACCESS Newswire / June 17, 2026 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has signed an LOI with a company in the United States to conduct clinical trials and testing for several potential nicotine products for CTT Pharma. A partnership with this company would allow CTT the ability to independently go to market in the United States utilizing our patented technology. CTT Pharma will notify shareholders as more information becomes available.
About CTT Pharmaceutical Holdings, Inc.
CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in the development and commercialization of thin film oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company's patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.
Forward-Looking Statements
Forward-looking statements include statements regarding the Company's plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
CTT Pharmaceutical Holdings, Inc.
813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
R.Lee--AT